Data completeness
2/8 — Basic
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUXIENCE is a CD20-directed cytolytic monoclonal antibody (rituximab-pvvr biosimilar) approved by FDA in July 2019 as a Pfizer-sponsored therapeutic. It binds to CD20 antigen on B cells, mediating their depletion across multiple hematologic and autoimmune indications. The product represents a Pfizer entry into the established rituximab biosimilar landscape.
$0.017BPart D
PeakAt peak commercial maturity with modest Part D spending ($17M, 2204 claims in 2023), indicating a niche position requiring focused specialty sales and medical science liaison support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RUXIENCE offers exposure to biosimilar competitive strategy, specialty pharmaceutical market access, and payer negotiation in a crowded immunology space. The peak-stage lifecycle and modest commercial footprint ($17M spend) suggest a smaller, focused team relative to blockbuster products, with career growth contingent on competitive pricing innovation and market share defense.
Brand Manager
Worked on RUXIENCE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.